UK markets close in 1 hour 14 minutes

AnaptysBio, Inc. (ANAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
21.42+0.04 (+0.19%)
As of 11:15AM EDT. Market open.

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801
United States
858 362 6295
https://www.anaptysbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees117

Key executives

NameTitlePayExercisedYear born
Mr. Daniel R. FagaPresident, CEO & Director867.12kN/A1980
Mr. Eric J. LoumeauChief Legal Officer685.59kN/A1963
Dr. James Newman Topper M.D., Ph.D.Advisor86.5kN/A1962
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.Chief Medical Officer656.36kN/A1975
Mr. Dennis M. MulroyChief Financial Officer448.81kN/A1955
Ms. Beth MuellerSenior Vice President of Human ResourcesN/AN/AN/A
Dr. Martin Dahl Ph.D.Senior Vice President of ResearchN/AN/AN/A
Mr. Benjamin StoneChief Business OfficerN/AN/AN/A
Mr. Douglas A. Rich M.B.A.Senior Vice President of CMCN/AN/A1969
Ms. Monique Da SilvaSenior Vice President of Corporate AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Corporate governance

AnaptysBio, Inc.’s ISS governance QualityScore as of 1 March 2024 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.